-
Mashup Score: 1Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients - PubMed - 5 day(s) ago
BCR is a heterogeneous population where overtreatment may present greater risk to patients than a disease course that is often indolent. Management of BCR should be individualized based on disease kinetics. Given the unique biology of BCR, future therapeutic research should emphasize an approach tha …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful? - 5 day(s) ago
Treating prostate cancer with intensified androgen blockade is widely accepted. Adding androgen receptor pathway inhibitors (ARPIs) to a backbone of androgen deprivation therapy (ADT) became standard of care for metastatic castrate-resistant prostate cancer more than a deca de ago. 1, 2 Since then, this intensified approach has improved overall survival (OS) compared with ADT alone in metastatic hormone-sensitive prostate cancer (HSPC) and in selected men with very high-risk localized and/or node-positive
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies - PubMed - 5 day(s) ago
Metastasis-free survival and overall survival of men with BCR who delay hormone therapy is long. This underscores the need to reevaluate when to start primary ADT in this patient population.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial - 5 day(s) ago
What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1
I feel compelled to tell this story openly. I hope it helps someone. I don’t want to waste time.
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
I feel compelled to tell this story openly. I hope it helps someone. I don’t want to waste time.
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
I feel compelled to tell this story openly. I hope it helps someone. I don’t want to waste time.
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
I feel compelled to tell this story openly. I hope it helps someone. I don’t want to waste time.
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
I feel compelled to tell this story openly. I hope it helps someone. I don’t want to waste time.
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Join our Cloud HD Video Meeting - 5 month(s) ago
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference room solution used around the world in board, conference, huddle, and training rooms, as well as executive offices and classrooms. Founded in 2011,…
Source: us02web.zoom.usCategories: General Medicine News, Hem/OncsTweet
We reviewed these conundrums recently in @CO_Oncology: https://t.co/2WgXFohpwn